Who are PPI-amoxicillin-clarithromycin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PPI, amoxicillin, metronidazole and clarithromycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ppi-amoxicillin-clarithromycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

PPI-amoxicillin-clarithromycin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PPI-amoxicillin-clarithromycin (PPI-amoxicillin-clarithromycin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination therapy with acid suppression. Area: Gastroenterology / Infectious Disease.

marketed Antibiotic combination therapy with acid suppression Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

PPI-amoxicillin-clarithromycin (PPI-amoxicillin-clarithromycin) — National Taiwan University Hospital. This is a triple-therapy combination that uses a proton pump inhibitor to reduce stomach acid while amoxicillin and clarithromycin work synergistically as antibiotics to eradicate Helicobacter pylori infection.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PPI-amoxicillin-clarithromycin TARGET	PPI-amoxicillin-clarithromycin	National Taiwan University Hospital	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome
PPI, amoxicillin, metronidazole and clarithromycin	PPI, amoxicillin, metronidazole and clarithromycin	Infante, Javier Molina, M.D.	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; metronidazole and clarithromycin target bacterial protein synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination therapy with acid suppression class)

Infante, Javier Molina, M.D. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PPI-amoxicillin-clarithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/ppi-amoxicillin-clarithromycin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing